Metin Çelik, PhD
Metin Çelik, PhD
President, Pharmaceutical
Technologies
International (PTI)
Metin Çelik is the founder and president of Pharmaceutical Technologies International, Inc., and is also a pharmaceutical processing research professor in the Department of Industrial Engineering at Rutgers University. Prior to that, he was a faculty member at Rutgers’ College of Pharmacy. Çelik received his BSc (Hons.) degree in pharmacy from Hacettepe University-Turkey and was awarded a PhD degree in Pharmaceutical Technology from Leicester Polytechnic-UK. Çelik worked at Sandoz-Switzerland and Sandoz-Turkey before he joined Smith Kline & French Laboratories to establish the first state-of-the-art compaction simulator system in the western hemisphere. He developed the second unit at Rutgers as the first such a unit in academia in the US and established an internationally recognized research center.
Çelik has organized more than 40 national and international symposia and short courses, published more than 30 research articles and book chapters, and made more than 150 presentations at industry and academic meetings. Çelik acted a consultant to FDA and roughly 45 pharmaceutical, nutraceutical, excipient, equipment companies, and law firms worldwide. He currently serves as a member of the editorial board or a reviewer for a numerous pharmaceutical journals. He is the past chair of the American Association of Pharmaceutical Scientists (AAPS) Process Development Focus Group and the founder and the past chair of the AAPS Excipients Focus Group.
Çelik's recent areas of interests include: process analytical technology; development of pharmaceutical expert systems, excipient databases, and management tools in the area of drug delivery technologies; use of compaction simulators in the preformulation and formulation of solid dosage forms; theory and practice of pharmaceutical compaction; excipient functionality testing; and pharmaceutical processing (including milling, mixing, granulation, tableting, and coating).
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.